Theorem Clinical Research

Drug Sponsors

Allergan board unanimously rejects revised Valeant proposal

Wednesday, June 11, 2014 12:54 PM

Allergan’s board of directors has unanimously determined the revised unsolicited proposal by Pershing Square and Valeant Pharmaceuticals International substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Celsion to acquire Egen

Wednesday, June 11, 2014 12:48 PM

Celsion, an oncology drug development company, and Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, have signed a definitive asset purchase agreement for Celsion to acquire substantially all of Egen’s assets, including its phase Ib DNA-based immunotherapy product candidate Egen-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

Merck to acquire Idenix for $3.85 billion

Monday, June 9, 2014 02:01 PM

Merck has agreed to acquire Idenix Pharmaceuticals for $24.50 per share in cash, for a total value of approximately $3.85 billion. The transaction has been approved by the boards of directors of both companies.

More... »

inVentiv Health, Aprecia Pharmaceuticals partner

Monday, June 9, 2014 01:58 PM

inVentiv Health, a life science knowledge and services company, and Aprecia Pharmaceuticals, a specialty pharmaceutical company, have formed an exclusive sales and marketing alliance. This partnership will launch the Aprecia brand, as well as provide comprehensive commercialization of Aprecia's pioneering technology platform and initial pharmaceutical products.

More... »

Biotech consortium launches KPI Therapeutics

Friday, June 6, 2014 12:51 PM

Five biotech firms and private investors have announced the launch of KPI Therapeutics, with the aim of speeding advancement of novel, promising drug candidates that can improve the quality of patients’ lives.

More... »

Asana BioSciences acquires drug discovery platform from Endo

Thursday, June 5, 2014 09:30 AM

Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International.

More... »

Celerion expands to Singapore, names Chew Lan Chong executive director

Wednesday, June 4, 2014 01:25 PM

Celerion has expanded its formal business presence in Singapore, and has named Dr. Chew Lan Chong, MBBS, MRCS, MSc, executive director, medical research, of its new operations. Chong has 10 years of direct operational experience leading clinical pharmacology units.

More... »

Teva to acquire Labrys Biologics for $825 million

Wednesday, June 4, 2014 12:57 PM

Teva Pharmaceutical Industries will acquire Labrys Biologics, a privately held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, broadening Teva’s array of biotechnology assets and capabilities.

More... »

Provence Technologies acquires Synprosis, rebrands as Provepep

Tuesday, June 3, 2014 09:22 AM

Provence Technologies Group, a specialist fine chemistry research group, has acquired Synprosis, a France-based company specializing in the chemical synthesis of peptides and proteins for therapeutic use. The financial terms of the agreement have not been disclosed.

More... »

Adaptimmune, GlaxoSmithKline collaborate on cancer therapies

Tuesday, June 3, 2014 08:05 AM

Adaptimmune, a biotechnology company developing TCR engineered T-cells to treat cancer, has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of its lead clinical cancer program.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs